ViiV la différence: VIKING-3 bolsters dolutegravir's case in multi-resistant HIV
This article was originally published in Scrip
ViiV Healthcare has presented the first Phase III results for dolutegravir in HIV-1 patients resistant to multiple antiretroviral therapies including other integrase inhibitors, providing the first large-scale view of the molecule's efficacy in this challenging population.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.